Kymera Therapeutics Inc (KYMR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kymera Therapeutics Inc (KYMR) has a cash flow conversion efficiency ratio of -0.029x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-27.11 Million) by net assets ($946.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kymera Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Kymera Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read KYMR total debt and obligations for a breakdown of total debt and financial obligations.
Kymera Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kymera Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Do-Fluoride Chemicals Co Ltd
SHE:002407
|
0.026x |
|
Pharmaron Beijing Co Ltd
SHE:300759
|
0.068x |
|
Rayonier Inc
NYSE:RYN
|
0.116x |
|
Archrock Inc
NYSE:AROC
|
0.144x |
|
The Swatch Group AG
F:UHRA
|
0.012x |
|
Coromandel International Limited
NSE:COROMANDEL
|
0.155x |
|
Figure Technology Solutions, Inc. Class A Common Stock
NASDAQ:FIGR
|
-1.593x |
|
Guanghui Energy Co Ltd
SHG:600256
|
0.066x |
Annual Cash Flow Conversion Efficiency for Kymera Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Kymera Therapeutics Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see KYMR market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $835.62 Million | $-194.50 Million | -0.233x | +10.59% |
| 2023-12-31 | $394.97 Million | $-102.83 Million | -0.260x | +16.64% |
| 2022-12-31 | $490.15 Million | $-153.09 Million | -0.312x | -11.33% |
| 2021-12-31 | $459.64 Million | $-128.95 Million | -0.281x | -190.37% |
| 2020-12-31 | $283.89 Million | $88.13 Million | 0.310x | +229.01% |
| 2019-12-31 | $-74.41 Million | $17.91 Million | -0.241x | -146.39% |
| 2018-12-31 | $-34.44 Million | $-17.86 Million | 0.519x | -- |
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidrad… Read more